PBS funding recommended for dual combination therapy in PAH

The PBS has signalled a move to subsidise dual combination therapy for patients with pulmonary arterial hypertension (PAH). A recommendation to subsidise combination therapy with an endothelin receptor antagonist (ERA) and phosphodiesterase-5 (PDE-5) inhibitor for patients with WHO Functional Class III and IV PAH was accepted by the Pharmaceutical Benefits Advisory Committee (PBAC) at its November ...